Clinical trials
Phase 2/3 trials in Italy with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 1 |
| 2014 | 4 |
| 2016 | 1 |
| 2017 | 3 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 40 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Catholic University of the Sacred Heart | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| University of Catanzaro | 2 |
| University of Milan | 2 |
| Università Politecnica delle Marche | 2 |
| A.O.U. Città della Salute e della Scienza | 1 |
| Alloksys Life Sciences B.V. | 1 |
| Azienda Ospedaliera San Giovanni Battista | 1 |
| Azienda Ospedaliera di Padova | 1 |
| Azienda Ospedaliero Universitaria Maggiore della Carita | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 4 |
| Coronavirus Infections | 2 |
| Heart Failure | 2 |
| Scleroderma, Systemic | 2 |
| Acute Lung Injury | 1 |
| Antiphospholipid Syndrome | 1 |
| Aspergillosis | 1 |
| Asthenozoospermia | 1 |
| Atherosclerosis | 1 |
| Blindness | 1 |
Trials
Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.